Radiation oncology company Accuray has been granted US Food and Drug Administration (FDA) approval for the Dose Control System, a new feature for the company’s TomoTherapy system.

The TomoTherapy system enables doses to be precisely applied to target structures while sparing healthy tissue.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Dose Control System ensures a stable output for treatments with a long duration, including total marrow and total body irradiation.

Accuray president and CEO Euan Thomson said that the Dose Control System can improve the TomoTherapy system’s performance.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact